The application and prospect of CDK4/6 inhibitors in malignant solid tumors

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which block the transition from the G1 to S phase of the cell cycle by interfering with Rb phosphorylation and E2F release, have shown potent antitumor activity and manageable toxicity in HR+/HER2− breast cancer patients. Some clinical trials involvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Qi, Guo, Xiang, Wang, Miao, Li, Yongfu, Sun, Xiaoyi, Li, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195725/
https://www.ncbi.nlm.nih.gov/pubmed/32357912
http://dx.doi.org/10.1186/s13045-020-00880-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195725/
https://www.ncbi.nlm.nih.gov/pubmed/32357912
http://dx.doi.org/10.1186/s13045-020-00880-8

Ejemplares similares